natgillin/translations-raw huggingface dataset:
The 12-week double-blind treatment included daily applications of Kentera or matching placebo gel. 
12-tedensko dvojno slepo zdravljenje je vključevalo vsakodnevno uporabo zdravila Kentera ali ustreznega gela s placebom.
As the stratum corneum is the rate-limiting step in transdermal delivery, any breach would provide direct access to the epidermis, potentially increasing penetration and facilitating the migration of the medicinal product to the blood stream. 
Stratum corneum je plast, ki omejuje transdermalni prenos, zato bi kakršnakoli razpoka omogočila neposreden dostop do epidermisa, kar bi lahko povečalo penetracijo in pospešilo migracijo zdravila v krvni obtok.
Plasma concentrations of oxybutynin begin to decline 24 hours after Kentera application. 
Koncentracije oksibutinina v plazmi se začnejo manjšati 24 ur po uporabi zdravila Kentera.
The untreated partners not protected by clothing demonstrated detectable plasma concentrations of oxybutynin (mean Cmax = 0.94 ng/ml). 
Pri nezdravljenih partnerjih, ki niso bili zaščiteni z oblačili, so opazili zaznavne koncentracije oksibutinina v plazmi (povprečna vrednost Cmax = 0,94 ng/ml).
Each sachet contains 1 g of gel. 
Ena vrečica vsebuje 1 g gela.
If the patch comes off: 
Če se obliž odlepi:
Based on clinical trial experience no dose adjustment is considered necessary in this population. 
Na podlagi izkušenj iz kliničnega preskušanja velja, da odmerka pri tej populaciji ni treba prilagajati.
The most commonly reported adverse reaction was dry mouth (Kentera 6.9%, placebo 2.8%). 
Najpogostejši neželeni učinek, o katerem so poročali, so bila suha usta (6,9 % pri zdravilu Kentera in 2,8 % pri placebu).
- Gently bend the patch and remove the first piece of protective liner, which covers the sticky surface of the patch. 
- Nežno upognite obliž in odstranite prvo plast zaščitne folije, ki pokriva lepljivo površino obliža.
Kentera delivers approximately 0.08 mg/kg/day. 
Zdravilo Kentera sprošča približno 0,08 mg/kg/dan.
Squeeze from the bottom of the sachet toward the open end. 
Iztisnite od dna vrečice proti odprtem koncu.
Plasma concentration of oxybutynin declines within 1 to 2 hours after removal of transdermal system(s). 
Koncentracija oksibutinina v plazmi pade v 1 do 2 urah po odstranitvi transdermalnega sistema / sistemov.
- If you experience incomplete bladder emptying during urination, the use of oxybutynin may increase this problem. 
- Če imate težave z nepopolnim praznjenjem mehurja med uriniranjem, lahko uporaba oksibutinina težavo še poveča.
Kentera contains alcohol and is considered flammable and should not come in contact with an open flame. 
Zdravilo Kentera vsebuje alkohol in je vnetljivo, zato ne sme priti v stik z odprtim ognjem.
In total 496 patients were exposed to Kentera in the randomised, double-blind, placebo-controlled 12week and the 14-week safety extension studies. 
Skupaj je bilo zdravilu Kentera v randomiziranih, dvojno slepih, s placebom nadzorovanih, 12-tedenskih in 14-tedenskih podaljšanih študijah varnosti izpostavljenih 496 bolnikov.
Select an approved site for the application of Kentera. 
Izberite odobreno mesto za nanašanje zdravila Kentera.
Injury, poisoning and procedural complications 
Poškodbe in zastrupitve in zapleti pri posegih občasni poškodbe
Kentera is formulated for daily application and is capable of maintaining therapeutic blood levels of oxybutynin. 
Zdravilo Kentera je pripravljeno za uporabo enkrat dnevno in lahko vzdržuje terapevtske ravni oksibutinina v krvi.
Consumption of grapefruit juice may also influence metabolism of oxybutynin. 
Tudi uživanje soka grenivke lahko vpliva na presnovo oksibutinina.
The recommended dose is one 3.9 mg transdermal patch applied twice weekly (every 3 to 4 days). 
Priporočen odmerek je 3,9 mg transdermalnega obliža dvakrat tedensko (vsake 3 do 4 dni).
Studies in animals have shown minor reproductive toxicity (see section 5.3). 
Študije na živalih so pokazale manjši vpliv na sposobnost razmnoževanja (glejte poglavje 5.3).
After the priming step is complete, 30 full doses will remain in the pump. 
Ko je polnjenje končano, je v črpalki še 30 odmerkov.
After applying the gel, hands should immediately be washed thoroughly with soap and water. 
Po nanašanju gela je treba roke takoj temeljito umiti z milom in vodo.
- Erythromycin a macrolide antibiotic (used to treat bacterial infections). 
- Makrolidni antibiotik eritromicin (uporablja se za zdravljenje bakterijskih okužb).
Try not to touch the sticky surface of the patch. 
Pri tem se ne dotikajte lepljive površine obliža.
- Tricyclic antidepressants (used to treat depression). 
- Triciklični antidepresivi (uporabljajo se za zdravljenje depresije).
You should not apply Kentera to the same site on consecutive days. 
Zdravila Kentera ne smete nanesti na isto mesto ob zaporednih dneh.
Oxybutynin is a racemic (50:50) mixture of R- and S-isomers. 
Oksibutinin je racemna (50 : 50) zmes R- in S-izomerov.
Physical activity subscale 
Podlestvica fizična aktivnost
Reductions in weekly incontinence episodes, urinary frequency, and urinary void volume were evaluated. 
Ocenjeno je bilo zmanjšanje tedenskih inkontinenčnih epizod, pogostost uriniranja ter volumen izpraznjenega urina.
Patients should be informed that alcohol may enhance the drowsiness caused by anticholinergic agents such as oxybutynin (see section 4.7). 
Bolnike je treba obvestiti, da alkohol lahko poveča dremavost, ki jo povzročajo antiholinergične zdravilne učinkovine, kot je oksibutinin (glejte poglavje 4.7).
Kentera is not recommended for use in children and adolescents under 18 years old. 
Otroci in mladostniki Uporaba zdravila Kentera pri otrocih in mladostnikih, mlajših od 18 let, ni priporočljiva.
Significant improvements in the quality of life evaluations measured during the study were also observed with Kentera. 
Pri zdravljenju z zdravilom Kentera so opazili tudi pomembna izboljšanja pri ocenjevanjih kakovosti življenja, ki so jih opravili med študijo.
Application should not be made to the same site on consecutive days. 
Zdravilo se ne sme nanašati na isto mesto v zaporednih dneh.
At a concentration of 0.4 mg/kg/day oxybutynin administered subcutaneously, the occurrence of organ anomalies is significantly increased, but is observed only in the presence of maternal toxicity. 
Pri koncentraciji 0,4 mg/kg/dan oksibutinina, odmerjenega subkutano, se pogostnost anomalij organov pomembno poveča, vendar so jih opazili samo v prisotnosti toksičnosti pri materah.
Step 4: Apply the second half of the patch to your skin. 
4. korak: Nalepite drugo polovico obliža na kožo.
Antimuscarinic activity resides predominantly in the R-isomer. 
Antimuskarinsko delovanje je predvsem prisotno v R-izomeru.
When oxybutynin is used during breast-feeding, a small amount is excreted in the mother's milk. 
Kadar se oksibutinin uporablja med dojenjem, se majhna količina izloči v materino mleko.
- Apply immediately to your skin; do not keep or store the patch outside the sealed sachet. 
- Nemudoma ga nanesite na kožo; obliža ne shranjujte izven zaprte zaščitne vrečke.
Daily incontinence episodes Baseline 
Dnevne epizode inkontinence
Any used or unused patches should be discarded according to local requirements or returned to the pharmacy. 
Vse uporabljene ali neuporabljene obliže odstranite v skladu z lokalnimi zahtevami ali jih vrnite v lekarno.
Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000). 
Pogostnost je opredeljena kot: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000) in zelo redki (<1/10.000).
The safety of Kentera was evaluated in patients with urge urinary incontinence in a randomised, double-blind, placebo-controlled, parallel group Phase 3 study that included 789 patients (with 389 patients receiving Kentera and 400 patients receiving placebo). 
Varnost zdravila Kentera so ocenili pri bolnikih z urgentno urinarno inkontinenco v randomizirani, dvojno slepi, s placebom nadzorovani študiji 3. faze z vzporednimi skupinami, v kateri je sodelovalo 789 bolnikov (389 bolnikov je prejemalo zdravilo Kentera, 400 bolnikov pa placebo).
- If you have a rare condition called myasthenia gravis that makes the muscles in the body become weak and tire easily. 
- Če imate redko bolezen, imenovano miastenija gravis, zaradi katere so mišice šibke in se hitro utrujajo.
To prime the pump, fully depress the pump mechanism repeatedly until gel is observed, then depress the pump one more time, and discard this portion of the medicinal product to assure precise dose delivery. 
Črpalko napolnite tako, da večkrat popolnoma pritisnete mehanizem črpalke, dokler ne opazite gela, nato ga pritisnite še enkrat in zavrzite ta del zdravila, da zagotovite natančno dovajanje odmerka.
You should not use Kentera if you are pregnant unless your doctor has told you to. 
Zdravila Kentera ne smete uporabljati, če ste noseči, razen če vam je zdravnik tako naročil.
No matter what day this happens, continue with the twice-a-week schedule that you have marked on your patch box. 
kateri dan se to zgodi, se držite svojega urnika nanosa dvakrat tedensko, kot ste označili na škatlici.
Two of the 14 untreated subjects participating in the clothing-to-skin contact regimen had measurable oxybutynin plasma concentrations (Cmax < 0.1 ng/ml) during the 48 hours following contact with treated subjects; oxybutynin was not detectable with the remaining 12 untreated subjects. 
Pri dveh od 14 nezdravljenih preiskovancev, ki so sodelovali pri režimu stika oblačila-na-kožo, so v 48 urah po stiku z zdravljenimi preiskovanci opazili zaznavne koncentracije oksibutinina v plazmi (Cmax < 0,1 ng/ml); pri preostalih 12 nezdravljenih preiskovancih oksibutinina niso zaznali.
Data on possible effects of the use of oxybutynin on human male and female fertility are not available. 
Podatkov o morebitnih vplivih oksibutinina na plodnost moških in žensk pri človeku ni.
2 transdermal patches 8 transdermal patches 24 transdermal patches 
2 transdermalna obliža 8 transdermalnih obližev 24 transdermalnih obližev
- Push the liner forward a little to loosen the edge. 
- Folijo potisnite nekoliko naprej, da se rob odpusti.
Electrocardiogram abnormal, electrocardiogram change, blood chloride increased 
Preiskave občasni nenormalen elektrokardiogram, sprememba elektrokardiograma, zvišana raven klorida v krvi
Release Liner Siliconised polyester 
Plast za sproščanje učinkovine silikonizirani poliester
Apply a single dose as soon as you realise you have missed an application. 
Uporabite enkratni odmerek, takoj ko ugotovite, da ste pozabili nanesti zdravilo.
Person-to-person transference 
Prenos z osebe na osebo
- Do not cut the sachet with scissors, which might damage the patch inside. 
- Vrečke ne odpirajte s škarjami, ker lahko poškodujete obliž.
If you forget to use Kentera 
Če ste pozabili uporabiti zdravilo Kentera
(N=400) Mean (SD) Median Mean (SD) Median 
Povprečje (SD) Mediana Povprečje (SD) Mediana
The expression of CYP3A and CYP3A4 may vary by as much as 40 fold due to genetic polymorphism. 
CYP3A in CYP3A4 lahko razlikuje tudi do 40-krat.
Patients should be informed that heat prostration (fever and heat stroke due to decreased sweating) can occur when anticholinergics such as oxybutynin are used in a hot environment. 
Bolnike je treba informirati, da lahko pride do vročinske kapi (zvišana telesna temperatura in vročinska kap zaradi zmanjšanega znojenja) pri uporabi antiholinergikov, kot je oksibutinin, v zelo vročem okolju.
Kentera led to consistent improvements in overactive bladder symptoms compared with placebo. 
Uporaba zdravila Kentera je konsistentno izboljšala simptome hiperaktivnega mehurja v primerjavi s placebom.
The Phase 3 study was a randomised, double-blind, placebo-controlled, parallel group study that included 789 patients. 
Ta študija 3. faze je bila randomizirana, dvojno slepa, s placebom nadzorovana študija vzporednih skupin, v kateri je sodelovalo 789 bolnikov.
- Biperiden, levodopa, or amantadine (used to treat Parkinson's disease). 
- Biperiden, levodopa ali amantadin (uporabljajo se za zdravljenje Parkinsonove bolezni).
Make sure to wear only one patch at a time and wear your patch continuously, until it is time to apply a new one. 
Prepričajte se, da naenkrat nanesete samo en obliž in da ga nosite nepretrgoma do zamenjave z novim.
Gently rub Kentera into your skin until it dries. 
Nežno vtrite zdravilo Kentera v kožo, dokler se ne posuši.
The R-isomer of oxybutynin shows greater selectivity for the M1 and M3 muscarinic subtypes (predominant in bladder detrusor muscle and parotid gland) compared to the M2 subtype (predominant in cardiac tissue). 
Oksibutininov R-izomer izkazuje večjo selektivnost za podtipe muskarina M1 in M3 (prevladujejo v mišici detruzorja mehurja in obušesni žlezi) v primerjavi s podtipom M2 (prevladuje v srčnem tkivu).
After 30 doses, discard the Kentera pump. 
Po 30 odmerkih črpalko Kentera zavrzite.
Kentera contains alcohol and is considered flammable. 
Zdravilo Kentera vsebuje alkohol in je vnetljivo.
Metabolites include phenylcyclohexylglycolic acid, which is pharmacologically inactive, and N-desethyloxybutynin, which is pharmacologically active. 
Med metaboliti sta tudi fenilcikloheksilglikolna kislina, ki je farmakološko neaktivna, in N-dezetiloksibutinin, ki je farmakološko aktiven.
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. 
- Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
Discard the protective liners. 
- Zavrzite zaščitno plast.
Each patch consists of a clear backing film that has the pharmaceutical ingredients coated on the side containing the protective backing film. 
Vsak obliž je sestavljen iz prozorne folije, farmacevtske sestavine pa so nanesene na stran, na kateri je zaščitna folija.
Cartons of 30 sachets. 
Škatla s 30 vrečicami.
In patients with overactive bladder, characterised by detrusor muscle instability or hyperreflexia, cystometric studies have demonstrated that oxybutynin increases maximum urinary bladder capacity and increases the volume to first detrusor contraction. 
Pri bolnikih z bolj aktivnim mehurjem, za katere je značilna nestabilnost detruzorske mišice ali povišana refleksivnost, so cistometrične študije pokazale, da oksibutinin poviša največjo kapaciteto urinskega mehurja in volumen poveča do prvega skrčenja detruzorja.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON ( Containing 30 sachets) 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA (s 30 vrečicami)
Following the application of Kentera, oxybutynin plasma concentration increases for approximately 7 days, reaching average maximum concentrations of 4 to 5 ng/ml. 
Po uporabi zdravila Kentera se koncentracija oksibutinina v plazmi poveča za približno 7 dni, pri čemer doseže povprečno največjo koncentracijo od 4 do 5 ng/ml.
If you stop using Kentera 
Če ste prenehali uporabljati zdravilo Kentera
Kentera has minor influence on the ability to drive and use machines. 
Zdravilo Kentera ima blag vpliv na sposobnost vožnje in upravljanja s stroji.
Kentera is packaged in a carton containing 1 multidose container with metering pump. 
Zdravilo Kentera je pakirano v škatlo, ki vsebuje 1 večodmerni vsebnik z odmerno črpalko.
If urinary tract infection is present, an appropriate antibacterial therapy should be started. 
Če gre za okužbo sečil, je treba začeti ustrezno zdravljenje z antibiotiki.
Since treatment with oxybutynin may cause decreased perspiration, there is an increased risk of fever and heat stroke if you are exposed to high environmental temperatures. 
Zdravljenje z oksibutininom lahko zmanjša potenje, zato obstaja povečano tveganje za zvišanje telesne temperature in toplotni udar, če ste izpostavljeni visokim temperaturam v okolju.
Like all medicines, Kentera can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo Kentera neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Women of childbearing potential/Contraception in males and females Women of childbearing age should be tested for pregnancy before beginning therapy, and during therapy utilise some form of pregnancy contraceptive. 
Pri ženskah v rodni dobi je treba pred začetkom zdravljenja opraviti preizkus nosečnosti, med zdravljenjem pa morajo uporabljati eno izmed oblik kontracepcije.
Squeeze the entire contents of the sachet onto your hand (palm or fingertips) or squeeze directly onto the application site. 
Iztisnite celotno vsebino vrečice na roko (dlan ali prste) ali jo iztisnite neposredno na mesto nanosa.
Step 3: Apply one half of the patch to your skin. 
3. korak: Na kožo nalepite polovico obliža.
The used patches should be folded in half, adhesive side inwards so that the release membrane is not exposed, placed in the original sachet and then discarded safely out of the reach of children. 
Uporabljeni obliž je treba prepogniti na pol, z lepljivo plastjo navznoter tako, da membrana za sproščanje ni izpostavljena, ga dati v originalno vrečko in nato varno odstraniti tako, da je zunaj dosega otrok.
Gel 1 multidose container with metering pump of 30 grams 
1 večodmerni vsebnik z odmerno črpalko s 30 grami
The efficacy and safety of Kentera were evaluated in patients with urge urinary incontinence in a single Phase 3 study. 
Klinična učinkovitost Učinkovitost in varnost zdravila Kentera so ocenili pri bolnikih z urgentno urinarno inkontinenco v študiji
Kentera transdermal patch, gel and gel in sachet: 
Zdravilo Kentera transdermalni obliž, gel in gel v vrečici:
During post-marketing use in this age group, cases of hallucinations (associated with anxiety manifestations) and sleep disorders correlated with oxybutynin have been reported. 
V obdobju trženja so pri tej starostni skupini poročali o primerih halucinacij (povezanih s pojavom tesnobe) in motenj spanja, ki so bili v korelaciji z oksibutininom.
Contains 1 transdermal patch. 
Vsebuje 1 transdermalni obliž.
The transdermal patches are individually contained in LDPE/paper laminate sachets and supplied in Patient Calendar Boxes of 2, 8 or 24 patches. 
Transdermalni obliži so posamično pakirani v LDPE/papirnate laminatne vrečke in zloženi v škatlice s koledarji s po 2, 8 ali 24 obližev.
The other ingredients are: Each patch contains triacetin, and acrylic adhesive solution. 
Pomožne snovi so: En obliž vsebuje triacetin in raztopino akrilnega adheziva.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON (Containing 2, 8 and 24 transdermal patches) 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA (vsebuje 2, 8 in 24 transdermalnih obližev)
If you are a woman of childbearing age, you should be tested for pregnancy before using Kentera. 
Če ste ženska v rodni dobi, morate pred uporabo zdravila Kentera opraviti preizkus nosečnosti.
- Press the entire patch firmly onto the skin with your fingertips. 
- Obliž trdno pritisnite na kožo s konicami prstov.
Also in conditions such as ulcerative colitis, and intestinal atony. 
Enako velja za bolezni, kot sta ulcerozni kolitis in intestinalna atonija.
This leaflet was approved in 
Navodilo je bilo odobreno
The oxybutynin, triacetin and acrylic adhesive are coated on clear PET/EVA backing film and covered with a siliconised polyester release liner. 
Oksibutinin, triacetin in akrilno lepilo so naneseni na prozorno zaščitno folijo iz PET/EVA in prekriti s silikonizirano plastjo za sproščanje iz poliestra.
- Without touching the sticky surface, firmly press the patch, adhesive face down, onto the part of the abdomen, hips or buttocks you have selected for application. 
- Brez da se dotaknete lepljive površine, nežno stisnite obliž z lepljivim delom navzdol na del trebuha, bokov ali zadnjice, kamor želite obliž nalepiti.
Anticholinergic medicinal products should be used with caution in patients who have autonomic neuropathy, cognitive impairment or Parkinson's disease. 
Antiholinergična zdravila je treba uporabljati previdno pri bolnikih z avtonomno nevropatijo, kognitivno okvaro ali Parkinsonovo boleznijo.
A total of 957 patients with urge urinary incontinence were evaluated in three controlled studies comparing Kentera to either placebo, oral oxybutynin and/or tolterodine long acting capsules. 
V treh kontroliranih študijah je sodelovalo skupaj 957 bolnikov z urgentno urinarno inkontinenco v primerjavi zdravila Kentera s placebom, peroralnim oksibutininom in/ali kapsulami tolterodina s podaljšanim sproščanjem.
If prime is lost during the use (no gel is dispensed after depressing the pump), repeat as instructed above to re-prime the pump. 
Če se med uporabo črpalka izprazni (črpalka po pritisku ne iztisne gela), jo znova napolnite skladno z navodili zgoraj.
A small amount of orally administered oxybutynin is excreted in the mother's milk. 
Majhna količina peroralno uporabljenega oksibutinina se izloča v materino mleko.
Oxybutynin administered orally is metabolised primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. 
Peroralno zaužit oksibutunin v glavnem presnavljajo citokromski encimski sistemi P450, še posebej CYP3A4, ki ga najdemo v glavnem v jetrih in steni drobovja.
Rotating approved application sites with each dose may help in reducing the risk of developing skin irritations. 
S spreminjanjem primernih mest nanašanja pri vsakem odmerku se zmanjša nevarnost draženja kože.
Patients on Kentera therapy should keep application sites covered with clothing when coming into contact with breast-feeding or pregnant women or breast-fed infants. 
Bolniki, ki uporabljajo zdravilo Kentera, naj mesto uporabe prekrijejo z oblačili, kadar so v stiku z doječimi ženskami ali nosečnicami ali z novorojenčki, ki se hranijo z dojenjem.
Apply a new Kentera patch twice weekly (every 3 to 4 days). 
Nov obliž zdravila Kentera namestite dvakrat tedensko (vsake 3 do 4 dni).
The volume of distribution was estimated to be 193 l after intravenous administration of 5 mg oxybutynin hydrochloride. 
Ocenjen volumen porazdelitve je 193 l po intravenskem odmerjanju 5 mg oksibutininijevega klorida.
Headache, somnolence 
- glavobol ali zaspanost
Travel subscale 
Podlestvica potovanje
Following the application of Kentera, oxybutynin plasma concentration increases for approximately 24 to 48 hours, reaching average maximum concentrations of 3 to 4 ng/ml. 
Po nanosu obliža Kentera naraste koncentracija oksibutinina v plazmi za približno 24 do 48 ur in doseže povprečno maksimalno koncentracijo od 3 do 4 ng/ml.
HOW TO USE KENTERA 
KAKO UPORABLJATI ZDRAVILO KENTERA
Anticholinergic medicinal products should be used with caution in patients who have hiatus hernia/gastro-oesophageal reflux and/or who are concurrently taking medicinal products (such as bisphosphonates) that can cause or exacerbate oesophagitis. 
Antiholinergična zdravila je treba pazljivo uporabljati pri bolnikih, ki imajo hiatusno kilo/gastro-ezofagealni refluks in/ali trenutno jemljejo zdravila (kot so bisfosfonati), ki lahko povzročijo ali poslabšajo ezofagitis.
Do not apply Kentera in an area that is not approved. 
Zdravila Kentera ne nanašajte na površino, ki ni primerna.
Fertility studies in rats suggest a 6 fold margin of safety in both male and female breeding adults when Kentera is administered as prescribed (see section 5.3). 
Študije plodnosti pri podganah so pokazale 6-kratno varnostno mejo pri razmnožujočih se odraslih samcih in samicah, kadar se zdravilo Kentera uporablja skladno z navodilom (glejte poglavje 5.3).
6 PHARMACEUTICAL PARTICULARS 6.1 List of excipients 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi
Thus based on current clinical evidence no need for dose adjustment in elderly patients is considered necessary. 
Zato velja, da na podlagi trenutnih kliničnih dokazov odmerka ni treba prilagajati.
- Dipyridamole (used to treat blood clotting problems). 
- Dipiridamol (uporablja se za zdravljenje težav s strjevanjem krvi).
Only apply Kentera to intact skin. 
Zdravilo Kentera nanesite samo na nepoškodovano kožo.
Be sure all of it sticks to your skin, even around the edges. 
Prepričajte se, da je obliž v celoti nalepljen na kožo, tudi ob robovih.